Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Traws Pharma (TRAW) Depreciation & Amortization (CF) (2016 - 2025)

Historic Depreciation & Amortization (CF) for Traws Pharma (TRAW) over the last 14 years, with Q3 2025 value amounting to $15000.0.

  • Traws Pharma's Depreciation & Amortization (CF) rose 65000.0% to $15000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $19000.0, marking a year-over-year increase of 3571.43%. This contributed to the annual value of $12000.0 for FY2024, which is 2500.0% down from last year.
  • Traws Pharma's Depreciation & Amortization (CF) amounted to $15000.0 in Q3 2025, which was up 65000.0% from $1000.0 recorded in Q2 2025.
  • In the past 5 years, Traws Pharma's Depreciation & Amortization (CF) registered a high of $15000.0 during Q3 2025, and its lowest value of $1000.0 during Q1 2025.
  • For the 5-year period, Traws Pharma's Depreciation & Amortization (CF) averaged around $3842.1, with its median value being $4000.0 (2021).
  • Over the last 5 years, Traws Pharma's Depreciation & Amortization (CF) had its largest YoY gain of 65000.0% in 2025, and its largest YoY loss of 7500.0% in 2025.
  • Quarter analysis of 5 years shows Traws Pharma's Depreciation & Amortization (CF) stood at $4000.0 in 2021, then changed by 0.0% to $4000.0 in 2022, then changed by 0.0% to $4000.0 in 2023, then tumbled by 50.0% to $2000.0 in 2024, then skyrocketed by 650.0% to $15000.0 in 2025.
  • Its Depreciation & Amortization (CF) was $15000.0 in Q3 2025, compared to $1000.0 in Q2 2025 and $1000.0 in Q1 2025.